Previous 10 | Next 10 |
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtu...
TORONTO, ON / ACCESSWIRE / February 22, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software, is pleased to announce that it has been recognized by the TSX Venture Exchange as one of the top 10 performing technology stock...
Itolizumab was associated with high clinical response rates at Day 15 and 29 Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169 Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host disease ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the SVB Securities Annual Global Biopharma Conference. Mana...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings of the ...
Metacrine ( NASDAQ: MTCR ) and Equillium ( NASDAQ: EQ ) have j ointly agreed to terminate their merger agreement . The deal, announced in September, would have had Equillium ( EQ ) issue stock amounting to ~$26M to fund the acquisition. No reason was given for ...
Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement. “Equillium first set out to acquire Metacrine in an all-stock transaction in early 2022, with the intent of adding cash runway in a very di...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited, in collaboration with Equillium, has initiated a Phase 2 clinical study of itolizumab in patien...
Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M ( ¥ 3.5B); eligible to receive up to approximately $138.5M ( ¥ 18.7B) in option exercise and milestone payments Ono to ...
Equillium press release ( NASDAQ: EQ ): Q3 GAAP EPS of -$0.40 misses by $0.02 . Cash, cash equivalents and short-term investments totaled $44.5 million as of September 30, 2022, compared to $57.6 million as of June 30, 2022. Equillium believes that its cash and investm...
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...